Age- and Concentration-Dependent Elimination Half-Life of 2,3,7,8-Tetrachlorodibenzo-p-dioxin in Seveso Children by Kerger, Brent D. et al.
Shorter elimination half-lives for 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) and
other polychlorinated dibenzo-p-dioxins and
polychlorinated dibenzofurans (PCDD/Fs)
have been reported in human infants (Kreuzer
et al. 1997; Leung et al. 2006) and in highly
exposed adults (Aylward et al. 2005; Leung
et al. 2005) compared with those in the gen-
eral population. However, few published
elimination half-life data are available for
young children and adolescents 1–18 years of
age. Needham et al. (1997/1998) presented
TCDD decay curves for a 50-year-old Seveso
male (initial TCDD concentration of 1,770
ppt) and a 6-year-old Seveso male (initial
TCDD concentration of 15,900 ppt) and
noted a much faster TCDD serum lipid decay
for the child, especially over the 6-year period
following exposure. Additional data on chil-
dren are needed to further validate the two
age-dependent PCDD/F half-life models that
have been proposed for estimating childhood
body burdens (Kerger et al. 2005; Kreuzer
et al. 1997). 
In this study we examined a database of
longitudinal TCDD measurements in the
blood lipids of children (ages 0.5–18 years)
exposed during the 1976 trichlorophenol reac-
tor explosion incident near Seveso, Italy. As
many as 10 sequential measurements were
made on some children. We evaluated changes
in elimination rate of TCDD in blood lipids as
influenced by age, latency from exposure,
TCDD concentration or mass in the body,
severity of chloracne, and body mass parame-
ters potentially inﬂuencing the half-life in chil-
dren, adolescents, and young adults. Our goal
was to identify central tendency trends for the
half-life versus age relationship that may be
used to estimate childhood body burdens, par-
ticularly for children 1–7 years of age, an age
range critical to understanding potential risks
of PCDD/F intake during childhood (Kerger
et al. 2005). 
Materials and Methods
Data from the Seveso incident include fairly
complete information on longitudinal blood
TCDD measurements, sampling date, expo-
sure zone, severity of chloracne, and age,
height, and weight at the time of sampling
(up to 16 years after the incident). Persons <
18 years of age in July 1976 with at least two
blood TCDD measurements were included
in the initial data evaluation, which com-
prised 27 females and 20 males within Zone
A. The analytical method for lipid TCDD
has been reported by Patterson et al. (1987),
and some clinical correlations have been
reported by Mocarelli et al. (1991).
The calculated half-life of TCDD was
based on one or more data pairs of serum lipid
TCDD concentrations for each individual. The
initial peak TCDD concentration in several
individuals occurred 3–12 months after July
1976, indicating continuing absorption or redis-
tribution among tissues. The elimination half-
life was calculated using the standard equation
as described by Galbaldi and Perrier (1982):
t1/2 = –0.693 (Δ time)
÷ [ln (TCDD concentration 
at subsequent sampling
÷ concentration at initial peak)]. [1]
The peak TCDD measurement between July
1976 and July 1977 served as the initial value
(A) in chronological sequence (A→B→C→D),
and data pairs (A–B, A–C, A–D) were used to
calculate half-life by the foregoing equation.
The initial value (A) is referred to as the initial
sample and the samples collected after A (B, C,
and D) are referred to as the subsequent sam-
ples. Undetected values were included in the
analysis at the stated detection limit. 
Some of the analyses used estimated values
for body mass index (BMI) and body fat mass
(BFM) relevant to the sampling time and indi-
vidual. BMI was calculated using measure-
ments of the metric height (H) in centimeters
and weight (W) in kilograms and the standard
equation:
BMI = 10,000 × W/H/H. [2] 
We calculated BFM by estimating the body fat
fraction correlated to BMI with age- and sex-
speciﬁc equations reported by Deurenberg et al.
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OBJECTIVE: Pharmacokinetic and statistical analyses are reported to elucidate key variables affecting
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) elimination in children and adolescents. 
DESIGN: We used blood concentrations to calculate TCDD elimination half-life. Variables examined
by statistical analysis include age, latency from exposure, sex, TCDD concentration and quantity in
the body, severity of chloracne response, body mass index, and body fat mass. 
PARTICIPANTS: Blood was collected from 1976 to 1993 from residents of Seveso, Italy, who were
< 18 years of age at the time of a nearby trichlorophenol reactor explosion in July 1976. 
RESULTS: TCDD half-life in persons < 18 years of age averaged 1.6 years while those ≥ 18 years of
age averaged 3.2 years. Half-life is strongly associated with age, showing a cohort average increase
of 0.12 year half-life per year of age or time since exposure. A signiﬁcant concentration-dependency
is also identiﬁed, showing shorter half-lives for TCDD concentrations > 400 ppt for children < 12
years of age and 700 ppt when including adults. Moderate correlations are also observed between
half-life and body mass index, body fat mass, TCDD mass, and chloracne response. 
CONCLUSIONS: Children and adolescents have shorter TCDD half-lives and a slower rate of increase
in half-life than adults, and this effect is augmented at higher body burdens. 
RELEVANCE: Modeling of TCDD blood concentrations or body burden in humans should take
into account the markedly shorter elimination half-life observed in children and adolescents and
concentration-dependent effects observed in persons > 400–700 ppt.
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obtain total kilograms of body fat. TCDD mass
in the body fat (in nanograms) was calculated
by multiplying BFM (in kilograms) and
TCDD concentration (in parts per trillion, or
nanograms TCDD per kilogram lipid) at the
time of blood sampling. 
Preliminary analysis of data correlations
indicated the expected data scatter from typi-
cal laboratory analytical error (e.g., ± 10–30%)
plus more substantial outliers that skewed the
central tendency trends. Many of the extreme
high and low half-life values were seen in the
ﬁrst year of measurements. These likely repre-
sent additional environmental exposures and/
or slow equilibration of the body TCDD
dose, both of which would make half-life cal-
culations less reliable for that period. Thus, all
data pairs occurring before July 1977 were
excluded (nine positive half-lives excluded:
0.1, 0.2, 0.3, 0.4, 0.6, 0.6, 0.8, 7.4, and 23.8
years). In other cases, outlier values occurred
as unusually high or low measurements within
the first 5 years of data (through 1981). We
excluded data pairs in this time period only if
the half-life was > 2-fold higher or lower than
the median of the values for that individual
and/or for others within a ± 3-year age span
(eight positive half-lives excluded: 0.7, 7, 8.1,
14.8, 18.5, 19.4, 27.9, and 30.7 years). 
We analyzed selected data groupings by
linear regression and Student’s t-test using the
algorithms in Microsoft Excel 2000 or using
the Z-statistic test (Freund 1970) for compar-
ing means among groups of greatly different
sample sizes. Selected subsets were defined
according to age, body fat parameters, chlor-
acne grade/status, and sex. Each data group-
ing was evaluated for age-dependent and
concentration-dependent effects on TCDD
elimination half-life. 
We evaluated relationships between
TCDD half-life and several independent vari-
ables that describe age, body composition, and
TCDD body burden using a series of mixed
regression models [see Supplemental Material
(http://www.ehponline.org/members/
2006/8884/supplemental.pdf)]. Due to an
observed TCDD concentration-dependent
effect on half-life with a transition point
around 700 ppt, TCDD concentration was
included as a categorical variable in a mixed
regression analysis reﬂecting the slopes above
and below the transition point. TCDD con-
centrations ≤ 700 ppt were given a value of
zero and concentrations > 700 ppt were given
a value of 1. Also, an interaction term, age ×
concentration, was included to evaluate the
effect of concentration on the slope of the age
versus half-life relationship.
Results 
Blood TCDD measurements analyzed here
include only those Seveso residents in Zone A
who were < 18 years of age in July 1976 and
had at least two measurements; this included
27 females and 20 males. The age and peak
TCDD concentration for each subject are
plotted in Figure 1. At the first sampling in
1976, the males ranged from 2.8 to 12.1 years
of age and had peak TCDD levels from 173
to 26,400 ppt. The females ranged in age
from 0.5 to 16.6 and had peak TCDD levels
from 54 to 56,000 ppt. Two females with lim-
ited data were excluded. One female had only
two samples taken (at 0.5 and 0.8 years of age,
both in 1976) and peak TCDD of 3,770 ppt,
and was excluded because of the less-than-1-
year-since-exposure criterion. The second
female was sampled at 8–11.8 years of age; she
had a peak TCDD level of 339 ppt and was
excluded on the basis of an outlier half-life
value (30.7 years). Thus, the final cohort is
comprised of 25 females and 20 males who
each contributed at least one data pair for the
half-life trend analyses.
The correlation between TCDD half-life
and age for the ﬁnal cohort is given in Figure 2,
showing a direct linear relationship with a mean
slope of 0.12 (95% confidence interval,
0.10–0.14) and a moderate correlation coefﬁ-
cient of 0.48. As illustrated in Table 1, this lin-
ear correlation between TCDD half-life and
age is dominated by measurements collected
after the individuals reached 18 years of age,
with ﬂatter slopes and poor correlation coefﬁ-
cients obtained for measurements before age
18. Similar trends were identiﬁed for subgroups
selected on the basis of latency since the expo-
sure incident, although correlation coefﬁcients
were stronger for age-dependency (Table 1).
Unfortunately, insufﬁcient data are available for
individuals < 12 years of age to derive a mean-
ingful regression analysis (r2 < 0.01). However,
the available data indicate a more gradual or
ﬂatter slope for the youngest members in this
cohort. 
Table 1 presents a series of selected mean
comparisons and linear regression of the
TCDD half-life versus age relationship.
Statistically significant influences (p < 0.05)
on average half-life were observed for BMI,
TCDD concentration (in subsequent blood
samples), TCDD mass in the body fat, chlor-
acne presence/severity, age, and latency. Sex
appeared to have a minor influence on half-
life, but the average half-life for males is not
significantly different than for females (p >
0.05), although Needham et al. (1994)
reported a longer serum TCDD half-life in
adult women compared with adult men.
With respect to BMI, heavier individuals
(who inherently have more adult measurements)
Figure 1. Peak TCDD concentration versus ages of Seveso children. Highest
reported blood lipid TCDD concentrations for 27 female and 20 male Seveso
residents who were < 18 years of age in 1976 and had at least two valid
samples.
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Figure 2. TCDD half-life versus age of Seveso children. Linear regression analysis
of entire cohort (25 females, 20 males) with the half-life since peak TCDD mea-
surement plotted against the person’s age at time of subsequent sampling. See
“Materials and Methods” for outliers identiﬁed and excluded. See also Table 1.
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Dioxin elimination half-life in Seveso childrenhad significantly higher mean half-lives than
leaner individuals in paired comparisons above
and below BMIs of 20 and 25 (Table 1).
However, the linear regression slope of half-life
versus age did not show consistent trends when
comparing the leaner and heavier BMI groups
in Table 1. Notably, there were considerable
differences in average age between the leaner
and heavier BMI groups that may have inﬂu-
enced the correlation. Also, data pairs for two
extremely obese females (17 years of age, BMI
36, half-life 2.9 years; and 22 years of age, BMI
39.2, half-life 1.7 years) were excluded from
the linear regression analyses for BMI > 20
because they substantially skewed the slope
(from 0.11 to 0.08) and correlation (r 2 from
0.42 to 0.05); however, their inclusion did not
alter the mean half-life comparison. 
A concentration-dependent effect appears
to coincide with the age-dependent effect on
half-life in children and adolescents (< 18 years
of age). This is indicated by significantly
shorter mean half-life at higher blood lipid
TCDD concentrations (> 700 ppt) and higher
TCDD mass in the body fat (> 7,000 ng)
compared to means for the paired, lower body
burden groups (Table 1). Subgroups selected
on the basis of these higher body burdens
demonstrated flatter and more poorly corre-
lated slopes for half-life versus age, although
these groups are less robust in terms of the
number of individuals and samples represented.
In contrast, the lower body burden groups
demonstrated slopes and correlation coefﬁcients
consistent with the whole cohort analysis.
Subgroups selected according to chloracne
response showed significantly shorter mean
half-lives with increasing severity of chloracne
compared with the subgroup with no chlo-
racne (Table 1). No statistically signiﬁcant sex-
related differences were identified, although
males consistently showed a slightly longer
average half-life than females in paired com-
parisons (Table 1).
Overlapping age- and concentration-
dependent trends are inherent to the selected
cohort in that most of the individuals with rel-
atively high peak TCDD levels (i.e., 26 of 29
persons > 1,000 ppt) were ≤ 12 years of age at
the time of the reactor explosion (Figure 1).
Table 1 shows similar average half-lives for per-
sons < 12 and < 18 years of age, and a signiﬁ-
cantly longer half-life for persons > 18 years of
age. Similarly, persons with > 15 years of
latency since exposure showed significantly
longer average half-life compared to persons
with < 15 years latency (Table 1). Figure 3 pre-
sents the TCDD half-life vs. blood lipid con-
centration relationship for children < 12 years
of age [i.e., data pairs for higher ages were
excluded; and TCDD values are the subse-
quent (not peak) concentrations]. An apparent
transition range is seen for shorter half-lives
around 300–400 ppt, with the longest half-life
in males at 1.2 years and in females at 1.7 years
for TCDD concentration > 400 ppt. Similar
analysis of the entire cohort showed no half-
lives > 2 years in those with > 2,000 ppt, and
only 2 half-life values > 2.2 years at > 700 ppt
(data not shown).
Overall, linear regressions of half-life versus
age in Table 1 show consistent slopes of
0.1–0.15 for the entire cohort and in the more
robust subgroups except those selected accord-
ing to age, latency, or TCDD concentration >
700 ppt. The 95% conﬁdence intervals (CIs)
for all linear regression slopes in Table 1 over-
lapped and were not signiﬁcantly different (p >
0.05; data not shown). Many of the signiﬁcant
differences between mean half-lives may be
associated with inadvertent age differences
among the selected subgroups.
Simple linear regression analysis revealed
relationships between body composition,
age, and TCDD half-life. Moderate correla-
tions were found for BFM vs. age [Equation
3], BMI vs. age [Equation 4], half-life vs.
BFM [Equation 5], and half-life vs. BMI
[Equation 6]:
BFM = 4.3 × age + 3.5; r2 = 0.42 [3]
BMI = 0.23 × age + 16.2; r2 = 0.24 [4]
Table 1. Statistical analysis of means and linear regression trends for TCDD half life vs. age for selected subgroups of Seveso children.
nfemale nmale Half-life (years)  Age (years) 
Subgroup (nvalues)( nvalues) (mean ± SD) (mean ± SD) Slope Intercept Correlation (R2)
BMI comparisons (mean ± SD)
All (BMI = 20.2 ± 3.4) 25 (66) 20 (50) 2.4 ± 1.3 16.8 ± 7.1 0.12 0.18 0.48
With BMI < 20 (BMI = 16.9 ± 1.7) 16 (27) 9 (17) 1.8 ± 1.1 13.1 ± 5.5 0.15 0.10 0.51
With BMI > 20 (BMI = 22.9 ± 2.2) 17 (28) 18 (29) 2.8 ± 1.2a 19.1 ± 7.4 0.11 0.75 0.42
With BMI < 25 (BMI = 19.5 ± 2.9) 24 (55) 15 (37) 2.2 ± 1.1a 15.6 ± 6.9 0.11 0.44 0.45
With BMI > 25 (BMI = 28.3 ± 4.3) 3 (4) 9 (9) 3.9 ± 1.4a,b 24.6 ± 5.3 0.19 0.74 0.51
TCDD concentration comparisons
With TCDD conc < 700 ppt (avg conc= 219 ± 179 ppt) 25 (58) 20 (51) 2.4 ± 1.3 17.1 ± 7.4 0.12 0.32 0.50
With TCDD conc > 700 ppt (avg conc = 1,400 ± 796 ppt) 10 (17) 3 (3) 1.6 ± 0.8c 13.9 ± 4.5 0.08 0.65 0.14
TCDD mass in the body comparisons
With TCDD mass < 7,000 ng (avg mass = 2,042 ± 1,763 ng) 25 (52) 20 (44) 2.5 ± 1.3 17.2 ± 7.5 0.13 0.31 0.52
With TCDD mass > 7,000 ng (avg mass = 11,898 ± 4,048 ng) 7 (15) 3 (3) 1.9 ± 1.0c 16.1 ± 5.0 0.10 0.26 0.27
Chloracne severity comparisons
No chloracne 8 (18) 12 (30) 2.7 ± 1.4 14.7 ± 7.1 0.14 0.54 0.53
Low grade (grade 1 or 2) 7 (23) 2 (6) 2.2 ± 1.2d 20.1 ± 7.8 0.12 –0.24 0.68
High grade (grade 3 or 4) 10 (35) 6 (15) 1.9 ± 1.1d,e 16.3 ± 6.2 0.14 –0.41 0.65
All chloracne (grades 1–4) 17 (58) 8 (21) 2.0 ± 1.1d,e 17.7 ± 7.0 0.13 –0.26 0.68
Sex comparisons
Male 0 20 (51) 2.5 ± 1.2 16.1 ± 6.8 0.12 0.59 0.46
Female 25 (75) 0 2.1 ± 1.3 17.0 ± 7.3 0.13 –0.04 0.53
Selected age group comparisons
< Age 12 13 (27) 9 (16) 1.5 ± 0.8 9.4 ± 1.6 –0.02 1.70 0.002
< Age 18 19 (40) 15 (33) 1.6 ± 0.9 11.4 ± 2.9 0.03 1.30 0.01
≥ Age 18 22 (34) 18 (18) 3.2 ± 1.2f 24.0 ± 4.1 0.18 –1.16 0.41
Selected latency from exposure comparisons
< 15 years latency 21 (52) 14 (33) 1.7 ± 0.9 12.9 ± 4.6 0.05 –1.10 0.06
> 15 years latency 23 (23) 18 (18) 3.5 ± 1.1g 24.6 ± 4.3 0.14 –0.02 0.31
Abbreviations: avg, average; conc, concentration. nfemale and nmale denote the number of female and male subjects included in the subset, and nvalues denotes the number of valid half-
life values included.
aSigniﬁcantly different mean value compared to the BMI < 20 group mean at p < 0.05 using the Z-statistic or Student’s t-test. bSigniﬁcantly different mean value compared to the BMI
< 25 group mean at p < 0.05 using the Z-statistic or Student’s t-test. cSignificantly different mean value compared to the paired group mean at p < 0.05 using the Z-statistic test.
dSigniﬁcantly different mean value compared to the Nonchloracne group mean at p < 0.05 using the Z-statistic test. eSigniﬁcantly different mean value compared to the Nonchloracne
group mean at p < 0.05 using Student’s t-test. fSigniﬁcantly different mean value compared to the < Age 12 and < Age 18 group mean at p < 0.05 using the Z-statistic or Student’s t-test.
gSigniﬁcantly different mean value compared to the < 15 years latency group mean at p < 0.05 using the Z-statistic or Student’s t-test.
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Kerger et al.half-life = 0.15 × BFM + 0.82; r2 = 0.33 [5]
half-life = 0.19 × BMI –1.4; r2 = 0.25. [6]
The mixed regression model that included
age, TCDD concentration category, and
TCDD concentration category × age indi-
cated that the subject effect was not statisti-
cally significant (p = 0.6). Accordingly, we
used a backward stepwise regression procedure
to identify the most appropriate multiple
regression model based on a starting model
that included age, TCDD concentration cate-
gory, and TCDD concentration × age. 
After accounting for the TCDD concen-
tration × age term’s effect on the slope of age,
the final model for TCDD concentration
≤ 700 ppt is 
t1/2 = 0.35 + 0.12 × Age. [7]
For TCDD concentration > 700 ppt the ﬁnal
model is 
t1/2 = 0.35 + 0.088 × Age, [8]
where t1/2 is the half-life and Age is the age at
time of subsequent sampling. The ﬁnal model
included age and TCDD concentration cate-
gory × age with an r2 of 0.71. The coefﬁcients
of both age (p < 0.0001) and TCDD concen-
tration × age (p = 0.028) were significantly
different than zero. This model indicates that
increased TCDD concentrations affect the
rate at which half-life increases with age rather
than the baseline half-life associated with an
age of 0 years. For two children with the same
age but TCDD concentrations below or
above 700 ppt, the child with a TCDD con-
centration < 700 ppt will have, on average, a
longer half-life than the child with a TCDD
concentration > 700 ppt.
The trends of individual persons for
TCDD half-life versus age (at subsequent sam-
pling) among those with ≥ 3 valid data pairs
and higher TCDD concentrations (> 2,000 ppt
at peak) show parallel slopes (Figure 4). Linear
regression by individual results in an average
slope of 0.12 ± 0.036 year/year (mean ± SD;
n = 10), consistent with overall data trends in
Figure 2. Similar analysis of individuals with
lower TCDD blood concentrations (< 2,000
ppt) shows an average slope of 0.14 ± 0.06
year/year (n = 7; data not shown). Thus, lower
blood concentrations seem to correspond to
slightly higher slope, although the difference is
small and not statistically different (p > 0.05).
Individual person trends for TCDD half-
life versus age among those with three or more
valid data pairs and ﬁrst exposure before 7 years
of age also show parallel slopes (Figure 5).
Linear regression by individual shows a mean
(± SD) slope of 0.09 ± 0.027 year/year (n = 7).
Thus, younger age at first exposure seems to
correspond to lower slope. This is consistent
with the ﬂatter slope observed in persons < 18
years of age for the total cohort in Table 1.
Individual person trends for TCDD mass
in body fat versus age among those with ≥ 3
valid data pairs and > 2,000 ppt peak TCDD
concentration in blood lipid are shown in
Figure 6. The TCDD mass parameter is
already adjusted for individual differences in
BMI and adipose volume. An initial phase of
rapid and substantial loss of TCDD mass from
the body is illustrated in Seveso children and
adolescents < 18 years of age and/or with body
burdens above approximately 7,000 ng (about
500 ppt in a 70-kg person with 20% body fat),
with transition to a more gradual slope of half-
life versus age for those > 18 years of age and
< 7,000 ng (Figure 6, Table 1). 
Discussion
Few published data are available on TCDD
elimination half-life in humans between the
ages of 1 and 18 years. This study shows a
dominant and consistent inﬂuence of age on
TCDD half-life for this cohort of 45 Seveso
residents exposed as children and adolescents
in 1976. Mean TCDD half-life for persons
< 18 years of age (or with < 15-year latency)
was about half that for persons > 18 years of
Figure 5. Individual trends for TCDD half-life versus age for peak exposure at
< 7 years of age. Subset includes only persons with ≥ 3 valid half-lives
and < 7 years of age at time of peak blood lipid TCDD concentration. Each sym-
bol represents an individual with at least three half-life estimates. Linear
regression was performed by individual showing parallel slopes (mean ± SD
0.09 ± 0.027 year/year) and 6 of 7 individuals with r 2 ≥ 0.93 (data not shown).
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Figure 4. Individual TCDD half-life versus age for peak TCDD > 2,000 ppt. Subset
includes only persons with ≥ 3 valid half-lives and peak blood lipid TCDD concen-
tration > 2,000 ppt. Each symbol represents an individual with at least three half-
life estimates. Linear regression was performed by individual showing parallel
slopes (mean ± SD 0.12 ± 0.036 year/year) and 7 of 10 individuals with r 2 ≥ 0.91
(data not shown). Similar trends were found for 7 individuals with 3 or more valid
half-lives and peak TCDD < 2000 ppt, showing parallel slopes (0.14 ± 0.062
year/year) and 5 of 7 individuals with r2 ≥ 0.88 (data not shown).
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Figure 3. TCDD half-life versus subsequent blood
lipid TCDD concentration for Seveso children < 12
years of age. Data subset excluding all measure-
ments in persons ≥ 12 years of age, including 13
females and 9 males (43 values). TCDD concentra-
tions above the transition range of 300–400 ppt cor-
respond to uniformly shorter half-lives. Similar
trends were apparent when all ages were
included, with an observed transition of approxi-
mately 700 ppt. See also Table 1.
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Dioxin elimination half-life in Seveso childrenage (or with > 15-year latency). The slope of the
half-life versus age plot averages 0.12 (95% con-
fidence interval, 0.10–0.14) years increased
TCDD half-life for each year of age. Age prob-
ably explains most of the variance in the indi-
vidual half-life trends, but is co-correlated with
TCDD concentration, BMI, and body fat
mass. Children < 12 years of age and/or ﬁrst
exposed < 7 years of age showed ﬂatter slopes
for the rate of increase in TCDD half-life with
age compared to the > 18-year age group.
Higher peak blood lipid TCDD concentra-
tions (> 400 ppt in children and > 700 ppt in
adults, or > 7,000 ng TCDD mass in the body
fat) were associated with shorter mean TCDD
half-life and a reduced slope of the half-life ver-
sus age correlation; that is, a greater excretion
rate was observed for the most highly exposed
Seveso children. These ﬁndings are consistent
with those of Aylward et al. (2005) who exam-
ined age- and concentration-dependent half-life
trends among Seveso adults and in a small
group of Austrian patients (Emond et al. 2004;
Geusau et al. 2002). Aylward et al. (2005)
reported that TCDD body burdens > 10,000
ppt in blood lipid corresponded to half-lives < 3
years in adults (e.g., 20–50 years of age). This
study identiﬁes even shorter TCDD half-lives
for children and adolescents, averaging 1.3 years
for females and 2.0 years for males < 18 years of
age, and showing a steady rate of increase in
half-life with age. Using the final regression
model for the Seveso child cohort (defining
half-lives above and below the 700 ppt transi-
tion point) that includes age at time of sam-
pling and TCDD concentration times age, a
21-year-old person with a background TCDD
level of 10 ppt in serum lipids would exhibit a
half-life of 2.9 years, and the same person with
a high TCDD body burden of 100,000 ppt
would exhibit a half-life of 2 years. By compari-
son, a child with comparable TCDD body bur-
dens at 7 years of age would exhibit a TCDD
half-life of 1.2 years at background exposure
levels and 0.9 years at 100,000 ppt. The simple
models for calculating TCDD half-life are
based primarily on measurements spanning the
range from childhood and early adolescence to
early adulthood. Models based primarily on
adult data (Aylward et al. 2005) may be more
appropriate for predicting age- and concentra-
tion-dependent half-life for older adults. 
Because adipose tissue volume increases
with age, the age-dependency of TCDD half-
life co-correlated (as expected) with parameters
generally reflecting adipose tissue volume.
Leaner body mass (BMI < 20) was associated
with shorter average half-life, whereas higher
BFM or BMI were generally associated with a
longer average half-life; however, the opposite
trend was seen in two extremely obese females
(BMI > 35, 17 and 22 years of age). One might
expect that the shorter half-life in leaner sub-
jects may reﬂect a higher TCDD concentration
gradient favoring excretion via fecal lipids
(Schlummer et al. 1998). The two clinically
obese females each demonstrated depuration of
most of their TCDD body burden before
becoming obese. The 17-year-old subject with a
BMI of 36 had a peak TCDD mass in body fat
of 7,600 ng at 1.7 years of age, which was
reduced to 2,200 ng by 7.9 years of age, when
her BMI was 22.7. The next blood measure-
ment at age 17 when clinical obesity was noted
corresponded to a TCDD mass of 2,600 ng,
showing little change in the 9 years since the
previous measurement. The 22-year-old subject
with a BMI of 39 had a peak TCDD mass of
about 56,000 ng at 5.9 years of age, which was
reduced to 3,900 ng at 11.4 years of age, when
her BMI was 23.7. The next blood measure-
ment, at 22 years of age, when clinical obesity
was present, corresponded to a TCDD mass of
only 410 ng, far lower than the body burden
about 10 years earlier. Thus, both clinically
obese subjects had apparently excreted most of
their TCDD body burden before becoming
obese. Severe obesity was apparently associated
with total sequestration (full retention) of the
TCDD body burden in a subject 17 years of
age, with moderate initial body burden (about
2,800 ppt in serum lipid and 7,600 ng TCDD
in the body) and with continued elimination in
a second subject, 22 years of age, with a higher
initial body burden (about 4,800 ppt in serum
lipid and 56,000 ng TCDD in the body).
Although this deserves further study, the num-
ber of overweight and obese subjects in this
child exposure cohort seems too small to pro-
vide meaningful insights.
In more detailed mixed regression model-
ing, the half-life in this population was signiﬁ-
cantly inﬂuenced by variables reﬂecting time
(age at subsequent sampling or initial age com-
bined with latency at subsequent sampling)
and TCDD body burden (initial concentra-
tion, subsequent concentration, and mass in
the body); however, age-related parameters
explained most of the variance. BFM was a sig-
nificant contributor only in models that
excluded contributions from the age-related
Figure 6. TCDD Mass in the body fat versus age of Seveso children for peak TCDD mass > 10,000 ng. Subset including only persons with ≥ 3 valid half-lives and peak
TCDD mass > 10,000 ng. Each symbol represents an individual with at least three TCDD mass determinations. (A) TCDD mass in linear scale; TCDD mass = 50,000
ng to help visualize trends apparent < 10,000 ng at time of sampling. (B) TCDD mass in log scale with no truncation of data. The estimated transition point for shorter
TCDD half-life is > 7,000 ng. See also Table 1. 
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Kerger et al.variables, but BMI was not a significant
contributor in the mixed regression models [see
Supplemental Material (http://www.ehponline.
org/members/2006/8884/supplemental.pdf)].
Complex cross-correlation between age- and
concentration-related effects on half-life may
have masked the less predominant inﬂuence of
body composition on TCDD half-life in this
study population.
Consistent with various pharmacokinetic
models based primarily on distribution of
TCDD into adipose volume (Carrier et al.
1995a, 1995b; Kerger et al. 2005; Kreuzer et al.
1997), an existing TCDD body burden
becomes sequestered in the larger/growing lipid
volume, leading to apparently longer half-life
with increasing age. However, growth of the
adipose tissue compartment during childhood
appears to explain only a small portion of the
age-related changes in TCDD excretion based
on the pattern of loss of TCDD mass in adi-
pose tissue (Figure 6). Also, the inverse correla-
tion between severity of chloracne and average
half-life (Table 1) may reﬂect greater excretion
via sebaceous glands and/or sequestration in the
skin among those most highly exposed (Iida
et al. 1997; Matsueda et al. 1995). Kerger and
James (2006) estimated that sebaceous oil secre-
tions and sloughing of skin epidermis might
account for twice as much PCDD/F elimina-
tion as that related to fecal excretion alone.
Enhanced biliary/fecal excretion and/or induc-
tion of liver binding proteins may also play a
role at these higher doses (Carrier et al. 1995a,
1995b; Leung et al. 1990a, 1990b).
The observed simple linear regression of
half-life versus age for the Seveso child cohort
(Figure 2) shows a predicted TCDD half-life
of 0.24 to 0.38 years at birth and 1 year of
age, respectively. A predicted TCDD half-life
of approximately 0.4 years in infants is consis-
tent with the pharmacokinetic model predic-
tions and observations of Kreuzer et al. (1997)
and Leung et al. (2006) for infants with back-
ground body burdens of PCDD/Fs. These
findings for TCDD half-life in Seveso chil-
dren are also consistent with results reported
by Leung et al. (2005) showing pentachlori-
nated dibenzofuran (PeCDF) and hexachlori-
nated dibenzofuran (HxCDF) half-lives in
people (17–80 years of age) highly exposed
during the Yusho and Yucheng poisoning
incidents in Japan and Taiwan, respectively.
The age-related increases in half-life reported
for PeCDF and HxCDF (combined cohort
trends of 0.18 and 0.12 year/year, respectively)
are similar to those reported here for TCDD
in the whole Seveso child cohort and in the
more robust data subsets (0.11–0.15 year/
year). Leung et al (2005) also identified dis-
tinctly shorter half-lives for those individuals
with the highest tissue concentrations (e.g.
> 3,000 ppt), similar to that seen for the entire
Seveso child cohort. 
In this study we aimed to identify central
tendency and more robust trends inﬂuencing
TCDD half-life in Seveso children. Several
caveats are evident from our analysis. First, sev-
eral individuals were observed to have increas-
ing blood lipid TCDD concentrations up to a
year after the explosion event in July 1976,
indicating further exposure and/or gradual
equilibration of the TCDD dose with blood
lipids. This ﬁnding indicates that the true peak
TCDD level may have been missed for the
many individuals with only one or two mea-
surements in the first year. Missing the peak
blood concentration would lead to higher-than-
actual estimated half-life values. Second, as
noted in “Materials and Methods,” we assumed
that nondetect values were present at the stated
detection limit. This would also have a ten-
dency to overstate the half-life if the true
TCDD concentration was lower. Third, a
number of data pairs were identified that
skewed trends considerably from the central
tendency, which led us to exclude a comparable
number of extremely low (e.g., < 0.6 year) and
extremely high (e.g., > 10 year) half-life values.
On balance, deleting these values reduced the
variance but did not change the robust central
tendency trends. Fourth, some individuals had
many sequential measurements (e.g., 4–10 data
pairs), whereas most had only a few (e.g., 1–2
data pairs). Also, the time span between
sequential blood TCDD measurements was
not uniform across subjects; the influence of
this factor on individual or population half-life
trends, if any, is unknown. Among individuals
with ≥ 3 valid data pairs, 10 (3 males/7 females)
had higher grade chloracne (grade 3–4), 3 (3
females) had lower grade chloracne (grade 1–2)
and 9 (7 males/2 females) had no chloracne.
Accordingly, the overall trends may overrepre-
sent female subjects with chloracne and males
without chloracne. And ﬁfth, the data set did
not contain a sufﬁciently large number of valid
data pairs to examine each a priori variable
thoroughly. Few observations were obtained for
very young children (< 7 years of age) or for
clinically obese individuals (BMI > 35). Thus,
the ﬁndings based on less robust data should be
interpreted with caution.
These findings may help validate the
assumptions used in pharmacokinetic models
that attempt to predict body burden trends for
TCDD (Kreuzer et al. 1997) and all PCDD/Fs
(Kerger et al. 2005) throughout the human
lifespan. An important element of TCDD body
burden modeling is to better understand the
underlying reasons responsible for the decrease
in lipid concentrations, which may be caused
by dilution in a larger adipose compartment, to
tissue-speciﬁc sequestration (e.g., to CYP1A2-
binding proteins in the liver), and/or to true
elimination of TCDD from the body. For
example, Kreuzer et al. (1997) presented a
pharmacokinetic model for TCDD that
accounts for age-related dilution with growth of
the adipose compartment, as well as contribu-
tions from losses related to metabolism and
excretion by partitioning to fecal fats, although
metabolism seems very limited in humans (Hu
and Bunce 1999; Rohde et al. 1999). 
The exact contribution of these factors is
not known and can vary depending on circum-
stances, but the available evidence suggests that
a) a lipid TCDD dilution effect from adipose
growth and b) fecal lipid excretion each are
likely to play a substantial role, with metabo-
lism being a moderate or minor contributor.
Excretion via fecal lipids may have a particu-
larly important role for infants and young chil-
dren, as their rate of fecal lipid excretion per
body weight basis is about 7 times higher than
that of adults (International Commission for
Radiological Protection 1975). In highly
exposed persons with maximal CYP1A2 induc-
tion, hepatic sequestration with subsequent
redistribution of the PCDD/Fs from fat to the
liver may be a dominant factor (Abraham et al.
2002; Grassman et al. 2000). And in persons
with severe chloracne, loss via sebaceous lipids
and skin desquamation may be appreciable.
Our observation that the decline in the total
mass of TCDD in Seveso child body fat (a
metric that is normalized for the effects of adi-
pose compartment growth) exceeds that plausi-
bly caused by growth (Figure 6) suggests that
excretion played an important role, particularly
that during the ﬁrst 5–10 years after the peak
body burden. 
With respect to children < 12 years of age,
the available data indicate short PCDD/F half-
lives for infants [0.4 years for TCDD at 0–1
years of age; based on data from Leung et al.
(2006)] and a consistent rate of half-life increase
with age based on the current study and other
data (Leung et al. 2005). Although the half-life
data on the 1- to 12-year age group are limited,
a slower or ﬂatter rate of increase compared to
older adolescents and young adults is suggested
in the current study. Therefore, use of the
higher half-life versus age slope relevant to early
adolescence through adulthood (e.g., 0.12
year/year) is suggested as a conservative yet
appropriate assumption for modeling TCDD
body burdens near background levels for
younger children.
The shorter half-life of TCDD in children
and adolescents may also be important with
respect to assessing health risks from environ-
mental exposures of potential concern. For
example, dioxins present in breast milk and
cow’s milk are of concern because of the higher
intake rates relative to body size for young chil-
dren (Agency for Toxic Susbstances and
Disease Registry 1998). The shorter half-lives
for TCDD in early childhood correspond to
much lower tissue concentrations and presum-
ably lower health risks during high intake peri-
ods of breast-feeding or higher cow’s milk
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half-life assumptions (Kerger et al., in press;
Kreuzer et al. 1997; Paustenbach et al. 2006;
Richter et al. 2006). Similar implications apply
for potential health risks from dioxin intake via
contaminated soils, which are expected to be
greater in younger children due in part to fre-
quent mouthing behaviors under age 5 (U.S.
Environmental Protection Agency 2000).
Further, the shorter half-life for TCDD during
early childhood and adolescence will inherently
inﬂuence the body burdens in reproductive-age
women, reﬂecting an attenuated inﬂuence of
childhood exposures on body burdens trans-
ferred to offspring, both in utero and via lacta-
tion (Richter et al. 2006). Further research is
warranted to assess these possible implications.
In summary, this study identifies signifi-
cantly shorter TCDD half-life in children and
adolescents compared to adults. Half-life is
influenced predominantly by age and blood
lipid TCDD concentration at the time of subse-
quent sampling, with linear equations providing
good ﬁt to the data above and below a transition
range of 400–700 ppt. Increasing body mass
index or body fat mass generally correspond to
longer half-life, consistent with a sequestration
effect on TCDD elimination as adipose volume
grows. However, assessment of “TCDD mass in
the body fat” indicates age- and concentration-
dependent elimination trends that are largely
independent of adipose volume. These pharma-
cokinetic considerations should be taken into
account when evaluating TCDD dose–response
relationships in epidemiologic studies and for
risk assessment purposes. 
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